Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells
View/ Open
Author
Sun, Michael
Ha, Ngoc
Pham, Duc-Hung
Frederick, Megan
Sharma, Bandana
Naruse, Chie
Asano, Masahide
Pipkin, Matthew E.
Published Version
https://doi.org/10.1038/srep42888Metadata
Show full item recordCitation
Sun, Michael, Ngoc Ha, Duc-Hung Pham, Megan Frederick, Bandana Sharma, Chie Naruse, Masahide Asano, Matthew E. Pipkin, Rani E. George, and To-Ha Thai. 2017. “Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells.” Scientific Reports 7 (1): 42888. doi:10.1038/srep42888. http://dx.doi.org/10.1038/srep42888.Abstract
Cbx3/HP1γ is a histone reader whose function in the immune system is not completely understood. Here, we demonstrate that in CD8+ T cells, Cbx3/HP1γ insufficiency leads to chromatin remodeling accompanied by enhanced Prf1, Gzmb and Ifng expression. In tumors obtained from Cbx3/HP1γ-insufficient mice or wild type mice treated with Cbx3/HP1γ-insufficient CD8+ T cells, there is an increase of CD8+ effector T cells expressing the stimulatory receptor Klrk1/NKG2D, a decrease in CD4+ CD25+ FOXP3+ regulatory T cells (Treg cells) as well as CD25+ CD4+ T cells expressing the inhibitory receptor CTLA4. Together these changes in the tumor immune environment may have mitigated tumor burden in Cbx3/HP1γ-insufficient mice or wild type mice treated with Cbx3/HP1γ-insufficient CD8+ T cells. These findings suggest that targeting Cbx3/HP1γ can represent a rational therapeutic approach to control growth of solid tumors.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318867/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731806
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)